Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study2024 · 15 citations
2. 2Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)2026
3. 3Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study2024 · 1 citations
4. 4Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study2025 · 5 citations
5. 5Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls2012 · 217 citations